UNSPSC 51142303: Naltrexone

This classification denotes an opiate antagonist with the molecular formula C20H23NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5S6W795CQM, chemically known as morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)- but generally known as naltrexone, which bears US NIH Compound Identifier 4428. European Medicines Agency schedules Naltrexone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09143MIG.

UNSPSC 51142303 Naltrexone, a Commodity code, shows a significant mismatch between its nominal scope and the state and local opportunities currently tagged to it. The recent solicitations under this code include a county health system's competitive bid for naloxone (a reversal agent for opioid overdose) and drug deactivation systems, a school district's multi-category request for career and technical education instructional resources and equipment, and a county facilities procurement for galvanized steel pallets—none of which align with naltrexone, an opioid antagonist medication. The naloxone opportunity is the only procurement marginally related to the code's pharmaceutical intent, but it names a different active pharmaceutical ingredient entirely and bundles it with non-pharmaceutical equipment.

The solicitation activity is geographically scattered across Florida (Seminole County), Texas (Klein Independent School District in Harris County), and Florida again (Hillsborough County). Seminole County's IFB 60459723LAS, posted June 30, 2026 and due July 26, 2026, sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and included E-Verify and drug-free workplace compliance. The misalignment of recent opportunities with the naltrexone code suggests either inconsistent tagging in the underlying procurement system or that this code tier is not actively used by state and local buyers for pharmaceutical procurement—the latter being the more likely explanation given the three diverse, unrelated opportunities. Practitioners should confirm whether naltrexone-specific procurement is actually underway before allocating pursuit resources to this code.